RxDoctor Payments Data

Shonta Collins

Family · Old Bridge, NJNPI 1689005589

Payments from drug & device makers

$1,230in general payments, 2019–2025

Across 48 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$600
  • AbbVie$209
  • Boehringer Ingelheim$190
  • Johnson & Johnson$108
  • GRT US Holding, Inc.$60
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$1,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,230 in reported general payments places this provider in the 80th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$332,704
Medicare patients
319
Services billed
3,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate160$1,017,966
Invega SustennaPaliperidone Palmitate161$414,292
AplenzinBupropion Hbr36$222,040
VraylarCariprazine Hcl114$145,768
EliquisApixaban168$91,846
RoxybondOxycodone Hcl26$67,193
VivitrolNaltrexone Microspheres23$39,867
JardianceEmpagliflozin66$33,908
OxycontinOxycodone Hcl54$31,866
PercocetOxycodone Hcl/Acetaminophen24$24,606
SuboxoneBuprenorphine Hcl/Naloxone Hcl26$19,719
Oxycodone Hcl671$19,215
RexultiBrexpiprazole12$18,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,819
JanuviaSitagliptin Phosphate27$14,736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$600$1,017,966160 claims
Johnson & JohnsonInvega Sustenna, Xarelto$108$424,703184 claims
AbbVieVraylar, Linzess$209$159,006140 claims
Boehringer IngelheimJardiance$190$33,90866 claims
Collegium Pharmaceutical, Inc.Xtampza Er$14$11,60629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,692 family providers in New Jersey.

Other family in Old Bridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →